Marcus Freeman has done a tremendous job in Year 3 of his tenure at Notre Dame. The former Ohio State Buckeyes linebacker ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

Despite his unceremonious exit from WWE in 2001, former WCW star Buff Bagwell expressed a desire to be welcomed back to WWE ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer.

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

Arcus Biosciences Stock Performance NYSE:RCUS opened at $15.46 on Friday. The company’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.06. Arcus Biosciences, Inc ...

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...